Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Ritter, Violetta; Krautter, Franziska; Klein, Diana; Jendrossek, Verena; Rudner, Justine

Ritter, Violetta; Krautter, Franziska; Klein, Diana; Jendrossek, Verena; Rudner, Justine.

Afiliación

Ritter V; Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Krautter F; Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Klein D; Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jendrossek V; Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Rudner J; Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany. justine.rudner@uk-essen.de.

Cell Death Dis ; 13(4): 367, 2022 Apr 19.

Article en En | MEDLINE | ID: mdl-35440079

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cell Death Dis Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google